Novartis Shares Fall Despite Higher Drug Sales Forecasts
Novartis lifts peak-sales forecasts for three drugs to $18 billion, but shares fall as its new outlook targets 5% annual growth through 2031.
Explore MarketSpeaker's latest reporting, research, and expert analysis tagged with "healthcare stocks", collected in one continuously updated archive.
Novartis lifts peak-sales forecasts for three drugs to $18 billion, but shares fall as its new outlook targets 5% annual growth through 2031.
Consumer staples, health care and utilities gained an average 13% as the Nasdaq 100 fell 13%, creating the widest defensive lead in 25 years, Morgan Stanley says.
Moderna raises its 2026 sales-growth forecast to 15%–25% after a profitable third quarter and discloses a GSK patent settlement with no payments for cross-licenses.
Novo Nordisk lifts its 2026 outlook after Q3 sales reach DKK79.20 billion and obesity revenue rises 22% at constant exchange rates, despite impairments.
Lilly’s retatrutide delivered more than twice Ozempic 2 mg’s average weight loss in a diabetes trial, as LLY shares gained 11.3% in a strong earnings week.
Health care, energy and other established businesses reach fresh intraday records as technology and chip stocks slide, exposing a widening split on Wall Street.
Merck reports $2.49 adjusted EPS and $18.09 billion in Q3 sales, raises its 2026 outlook and expands Keytruda Qlex revenue as MRK gains in premarket trading.
Roche agrees to license Zymeworks’ experimental ZW209 cancer treatment for $55 million upfront, with further payments tied to development and commercial milestones.
MANE closes 4.05% higher after Veradermics reports positive Phase 3 results for oral VDPHL01, while longer-term data and regulatory hurdles remain.